Francis Collins, MD, PhD, will step down as director of the National Institutes of Health (NIH) at the end of the year; the Biden administration ends a ban on federal funds for clinics that provide abortion referrals; the Pfizer/BioNTech COVID-19 vaccine is 90% effective in preventing hospitalization and death 6 months after the second dose.
Francis S. Collins, MD, PhD, announced he will step down as director of the National Institutes of Health (NIH) at the end of this year, after having served 3 US presidents for more than 12 years. Collins, the longest serving presidentially appointed NIH director, first took office on August 17, 2009, under the Obama administration; he previously served as the director of the National Human Genome Research Institute from 1993 to 2008. During his tenure, several initiatives were proposed and implemented to address growing health issues, including in Alzheimer disease, cancer, and opioid use disorder.
As reported by The New York Times, the Biden administration yesterday reversed a policy established under the Trump administration that barred clinics that provide abortion referrals from receiving federal family planning funds. Starting November 8, the new regulation will restore the Title X federal family planning program to how it was constructed under the Obama administration, and clinics can again refer women seeking abortions to a provider without risking the loss of this funding. Groups representing the affected clinics said the new policy will lead to the return of approximately 1300 local facilities that had left the funding program in protest of the policies made under Trump.
According to research published yesterday in The Lancet by investigators from Pfizer and the Kaiser Permanente Southern California health system, the Pfizer/BioNTech COVID-19 vaccine was shown to remain 90% effective in protecting against hospitalization and death from the virus and its variants up to 6 months after the second dose. As reported by The Washington Post, the study of more than 3.4 million people also showed that the vaccine’s efficacy against preventing infection waned over time, from 88% to 47% in the 6 months after the second dose.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More